 |
|
Dopamine Agonist Treatment of Schizophrenia With N-Propylnorapomorphine
Carol A. Tamminga, MD;
Michael D. Gotts, MD;
Gunvant K. Thaker, MD;
Larry D. Alphs, MD;
Norman L. Foster, MD
Arch Gen Psychiatry. 1986;43(4):398-402.
Abstract
• We administered N-propylnorapomorphine, a potent aporphine-family dopamine (DA) agonist, to schizophrenic patients with active psychotic symptoms. After acute administration a significant antipsychotic action of N-propylnorapomorphine, maximal at an oral dose of 19 mg, was noted. The antipsychotic action predominated in subjects with neuroleptic-responsive symptoms, not in neuroleptic-nonresponders. However, when N-propylnorapomorphine was administered on a subchronic dosage schedule, no antipsychotic effect occurred. These observations suggest a rapid-onset tolerance phenomenon of psychosis to N-propylnorapomorphine and are consistent with results from preclinical experiments. These data support the idea that the acute antipsychotic response of DA agonists is mediated by the DA autoreceptor but fail to provide evidence for the potential clinical usefulness of this treatment approach.
Author Affiliations
From the Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore.
Footnotes
Accepted for publication April 8, 1985.
Reprint requests to Maryland Psychiatric Research Center, Department of Psychiatry, PO Box 21247, Baltimore, MD 21228 (Dr Tamminga).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment
Yang and Chen
Neuroscientist 2005;11:452-470.
ABSTRACT
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Grunder et al.
Arch Gen Psychiatry 2003;60:974-977.
ABSTRACT
| FULL TEXT
|
